Conivaptan

Conivaptan
	File:Conivaptan structure.svg
Clinical data
Routes of; administration	iv
Pharmacokinetic data
Bioavailability	N/A
Identifiers
	IUPAC name N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-; 6(1H)-yl)carbonyl)phenyl)-; (1,1'-biphenyl)-2-carboxamide;
CAS Number	210101-16-9;
PubChem CID	151171;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C32H26N4O2
Molar mass	498.583

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Conivaptan (vaprisol®, YM 087) is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in heart failure. It is marketed by Astellas Pharma Inc.

Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). Effectively, it causes iatrogenic nephrogenic diabetes insipidus.

Clinical data
File:Conivaptan structure.svg
Routes of administration	iv
Pharmacokinetic data
Bioavailability	N/A
Identifiers
IUPAC name N-(4-(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin- 6(1H)-yl)carbonyl)phenyl)- (1,1'-biphenyl)-2-carboxamide
CAS Number	210101-16-9
PubChem CID	151171
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₃₂H₂₆N₄O₂
Molar mass	498.583